Phase 2 N=34 AIDS 347: IL-6 Blockade in Treated HIV Infection
HIV Infections
Primary: Number of Grade 2 or Greater AEs — 10; 2 Participants — p=0.07
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=5,012 HIV Rapid Testing & Counseling in Sexually Transmitted Disease (STD) Clinics in the U.S.
HIV/AIDS · Sexually Transmitted Infections
Primary: STI Incidence — 250; 226 participants
N/A N=216 Treatment Advocacy Intervention for HIV-Positive African Americans
HIV
Primary: Medication Adherence — 77.96; 80.13; 64.87; 76.13 Percentage of doses taken — p=.005
N/A N=121 Living Well Project for Persons With AIDS
Acquired Immunodeficiency Syndrome (AIDS)
Primary: Change in Quality of Life — 5.87; 5.17; 5.68; 5.06 score on a scale
Phase 2 N=12 Chemotherapy and HAART to Treat AIDS-related Primary Brain Lymphoma
AIDS-Related-Primary Central Nervous System Lymphoma
Primary: Number of Patients Alive at 2 Years Without Recurrent Brain Lymphoma or Severe Neurocognitive Defects — 8 Participants
Phase 2 N=43 Combination Chemotherapy and Rituximab in Treating Patients With Newly Diagnosed AIDS-Related B-Cell Non-Hodgkin's Lymphoma
Lymphoma
Primary: Complete Response Rate (Complete Response and Complete Response Unconfirmed) Defined as Disappearance of All Evidence of Disease Based on Radiographic Findings on CT or…
N/A N=23 Sistas Informing Sistas on Topics About AIDS and Prevention (SISTA-P)
Health Behavior, Risky · Health Knowledge, Attitudes, Practice · Health-Related Behavior
Primary: Feasibility of the Intervention Scale — 4.78 units on a scale — p=.001
Phase 4 N=1,771 Antiretroviral Therapy for Advanced HIV Disease in South Africa
HIV
Primary: Progression to AIDS or Death in tx naïve Pts With Adv HIV dx in the Four Randomly Assigned Regimens. — 93; 77; 70; 80 participants
N/A N=175 Incidence and Prevalence of Cancer in People Living With HIV/AIDS at Cancer Centers in Latin America
HIV Infection · Human Immunodeficiency Virus 1 Positive · Malignant Neoplasm
Primary: Estimates of Site-specific Incident Cases and Site-specific Prevalence of Cases Presenting With Human Immunodeficiency Virus (HIV) and Cancer Presenting Over 9 Months at…
N/A N=512 Adherence Support Intervention for Persons Living With HIV/AIDS (PLWHA) on Antiretroviral Therapy (ART) in Estonia
HIV · AIDS · Medication Adherence
Primary: Antiretroviral Therapy (ART) Adherence (Self-reported 3-day Recall Measure) — 142; 139; 6; 12 participants
Phase 3 N=192 Antiretroviral Therapy (ART) Alone or With Delayed Chemo Versus ART With Immediate Chemo for Limited AIDS-related Kaposi's Sarcoma
HIV-1 Infection · Kaposi's Sarcoma
Primary: Kaposi Sarcoma (KS) Status at Week 48 Compared to Study Entry — 43; 47; 13; 9 Participants — p=0.911
Phase 2 N=121 Modulation of Immune Activation by Aspirin
HIV-1 Infection
Primary: Change in sCD14 From Baseline to Week 11/12 — 0.99; 1.03; 0.97 fold change — p=0.70
N/A N=215 Incidence of HANA Conditions in HIV-infected Individuals
HIV · Metabolic Syndrome · Osteopenia
Primary: Prevalences of HIV-associated Non-AIDS Conditions (HANA) — 69; 15; 30; 4 Participants — p=0.244
N/A N=7 Automated Medication Platform With Video Observation and Facial Recognition to Improve Adherence to Antiretroviral Therapy in Patients With HIV/AIDS
HIV Infections
Primary: Rate of Medication Adherence — 2; 1 Participants
Phase 1 N=18 Psilocybin-assisted Group Therapy for Demoralization in Long-term AIDS Survivors
Distress · Depression · Grief
Primary: Number of Participants Who Experienced Treatment-related Adverse Events as Assessed by NIH Division of AIDS Table for Grading the Severity of Adult and Pediatric Adverse…
Phase 2 N=3 Lenalidomide in Treating Patients With AIDS-Associated Kaposi's Sarcoma
AIDS-Related Kaposi Sarcoma · Recurrent Kaposi Sarcoma
Primary: Maximum Tolerated Dose of Lenalidomide Defined as the Dose Level at Which 0/6 or 1/6 Subjects Experience Dose Limiting Toxicity (DLT) With the Next Higher Dose Having at…
N/A N=28 Youth Ending the HIV Epidemic
HIV/AIDS · Mobile Health · Young Adults
Primary: Feasibility: Rate of Participant Retention — 22 Participants
Phase 2 N=40 Impact of Valganciclovir on Severe IRIS-Kaposi Sarcoma Mortality: an Open-label, Parallel, Randomized Controlled-trial.
Kaposi Sarcoma · Human Immunodeficiency Virus · Immune Reconstitution Syndrome
Primary: Number of Participants Who Died of Immune Reconstitution Inflammatory Syndrome Associated to Kaposi Sarcoma (IRIS-KS) — 0; 3 Participants
Phase 3 N=184 Impact of a Dolutegravir-based Regimen on Early Mortality of AIDS Patients
Severely Immunocompromised HIV Patients
Primary: Early Mortality — 9; 13 Participants
N/A N=10 Evaluating Quality of Life in Patients With AIDS-Associated Kaposi Sarcoma Treated With Bleomycin and Vincristine
AIDS-Related Kaposi Sarcoma · Human Immunodeficiency Virus 1 Positive
Primary: Total Score on Quality of Life Assessed Using Functional Assessment of Cancer Therapy-General (FACT-G) Questionnaire — 56.9 score on a scale
Phase 2 N=594 Improving Treatment Adherence in HIV-Infected Individuals
HIV Antiretroviral Therapy (ART) Adherence · Health Behavior
Primary: AIDS Clinical Trials Group (ACTG) 3-day Recall Measure of Doses Taken — 72.89; 75.46; 74.86; 77.33 percent with 100% adherence — p=0.12
N/A N=36 Brief Acceptance-Based Retention Intervention for Newly Diagnosed HIV Patients
HIV/AIDS
Primary: Number of Participants Meeting Retention in HIV Medical Care Guidelines at 52 Weeks — 20; 16 Participants
N/A N=120 HIV And Parasitic Infection (HAPI) Study
HIV Coinfection
Primary: Number of Participants With and Without Intestinal Parasitic Infection — 36; 84 Participants
N/A N=71 AllyQuest Adherence App Intervention for HIV-positive Men Who Have Sex With Men and Transgender Women: Pilot Trial
Hiv · HIV/AIDS · Medication Adherence
Primary: Intervention Feasibility: Average Proportion of Days of Any App Use — 0.64; 0.40; 0.27; 0.64 proportion of days
Phase 4 N=27 Implementation of Onsite, Rapid ART Initiation Among People Who Inject Drugs Living With HIV at Syringe Services Program
Harm Reduction · HIV Infections · Drug Use
Primary: Percentage of Participants With HIV Viral Load Suppression — 11 Participants
N/A N=328 Impact of Antiretroviral Therapy on Metabolic, Skeletal, and Cardiovascular Parameters
HIV Infection
Primary: Annual Rate of Change in Right Common Carotid Artery Intima-media Thickness (CIMT) — 8.2; 10.7; 12.9 micron/year — p=0.013
Phase 4 N=806 Immediate Versus Deferred Start of Anti-HIV Therapy in HIV-Infected Adults Being Treated for Tuberculosis
HIV Infection · Tuberculosis
Primary: Percent of Participants Who Survived Without AIDS Progression. — 13; 16 percent of participants — p=0.45
Phase 4 N=70 Tuberculosis and Human Immunodeficiency Virus (HIV) Immune Reconstitution Syndrome Trial (THIRST)
HIV · Tuberculosis
Primary: Number of Serious Adverse Events (SAEs) — 12; 7 Events
N/A N=100 Video Information Provider for HIV-Associated Non-AIDS (VIP-HANA) Symptoms
HIV (Human Immunodeficiency Virus) · AIDS (Acquired Immunodeficiency Syndrome)
Primary: Symptom Burden Score — 1.08; 1.06; 0.83; 0.71 score on a scale — p=0.02
N/A N=322 HIV Oral Testing Infographic Experiment
HIV/AIDS
Primary: HIV Self-testing Knowledge — 3.24; 3.79 score on a scale